The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 343-349

  Du, Gui Qiang ^a   Zhou, Long ^a   Chen, Xiao Yue ^a   Wan, Xiao Ping ^a   He, Yin Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Endometrial cancer; GPR30; Hydroxytamoxifen; Tamoxifen

Indexed keywords

ESTRADIOL; G PROTEIN COUPLED RECEPTOR 30; HYDROXYTAMOXIFEN; MITOGEN ACTIVATED PROTEIN KINASE; RNA; TAMOXIFEN;

ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UP-REGULATION;

EID: 84862822293     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.161     Document Type: Article

References (27)

1. Pike M.C., Pearce C.L., Wu A.H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004, 23:6379-6391.
2. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nature Reviews Cancer 2006, 6:360-368.
3. Scott J.A., McGuire W.L. New molecular markers of prognosis in breast cancer, endocrine-dependent tumors 1991, Raven, New York, 179-196.
4. Jordan V.C., Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine reviews 1999, 20:253-278.
5. McDonnell D.P. The molecular pharmacology of SERMs. Trends in Endocrinology and Metabolism 1999, 10:301-311.
6. Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E., Perlman J.A., Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. Journal of the National Cancer Institute 1999, 91:1654-1662.
7. Jamil A., Croxtall J., White J. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells. Journal of molecular endocrinology 1991, 6:215-221.
8. *. American Journal of Obstetrics and Gynecology 1997, 176:129-137.
9. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endome-trial and breast tumor growth in the athymic mouse. Cancer Research 1988, 48:812-815.
10. Thomas P., Pang Y., Filardo E., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624.
11. E. Filardo, Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF (2000).
12. E.J. FILARDO, Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis, Molecular Endocrinology (2002).
13. Wang C., Prossnitz E.R., Roy S.K. Expression of G protein-coupled receptor 30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones. Endocrinology 2007, 148:4853.
14. Baquedano M.S., Saraco N., Berensztein E., Pepe C., Bianchini M., Levy E., Goni J., Rivarola M.A., Belgorosky A. Identification and developmental changes of aromatase and estrogen receptor expression in prepubertal and pubertal human adrenal tissues. Journal of Clinical Endocrinology & Metabolism 2007, 92:2215.
15. Vivacqua A. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Molecular Endocrinology 2005, 20:631-646.
16. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Research 2007, 67:1859.
17. He Y.-Y., Cai B., Yang Y.-X., Liu X.-L., Wan X.-P. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Science 2009, 100:1051-1061.
18. He Y.Y., Du G.Q., Cai B., Yan Q., Zhou L., Chen X.Y., Lu W., Yang Y.X., Wan X.P. Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. Journal of Cancer Research and Clinical Oncology 2012, 1-9.
19. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625.
20. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., Pearl M.L. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000, 21:1461.
21. Lee H., Jiang F., Wang Q., Nicosia S.V., Yang J., Su B., Bai W. MEKK1 activation of human estrogen receptor α and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Molecular Endocrinology 2000, 14:1882-1896.
22. Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 1997, 11:657-666.
23. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., Andò S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 2004, 279:27008.
24. Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., Fuqua S.A.W., Ando S., Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF in estrogen receptor-positive cancer cells. Molecular Endocrinology 2009, 23:1815-1826.
25. Filardo E., Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends in Endocrinology and Metabolism 2005, 16:362-367.
26. H.O. Smith, K.K. Leslie, M. Singh, C.R. Qualls, C.M. Revankar, N.E. Joste, E.R. Prossnitz, GPR30: a novel indicator of poor survival for endometrial carcinoma, American Journal of Obstetrics and Gynecology 196 (2007) 386 e381-386. e311.
27. T. Ignatov, H. Eggemann, A. Semczuk, B. Smith, J. Bischoff, A. Roessner, S.D. Costa, T. Kalinski, A. Ignatov, Role of GPR30 in endometrial pathology after tamoxifen for breast cancer, American Journal of Obstetrics and Gynecology 203 (2010) 595 e595-599.e516.